---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-089329"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T14:10:45.893030+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma Q2 net loss widens to $2.7M, cash $33.3M; merger with Oruka ongoing

## Summary
- Net loss $2.7M ($0.18/sh) vs $1.5M ($0.10) in Q2 2023, driven by $1.3M increase in G&A expenses.
- Cash $33.3M as of June 30, 2024, down from $37.4M at Dec 31, 2023; expects to fund ops through end of 2025.
- G&A expenses rose to $3.0M from $1.7M due to $0.9M merger-related professional fees and $0.4M CEO termination benefits (Dr. Bristow resigned April 3, 2024).
- Merger with Oruka Therapeutics remains pending; if not completed, company may pursue dissolution/liquidation.
- R&D expenses fell to $0.1M from $0.3M due to reduced headcount and end of grants.

## SEC filing metadata
- accession: 0000950170-24-089329
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000095017024089329/0000950170-24-089329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000095017024089329/abio-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-089329
- JSON: https://secwatch.observer/filing/0000950170-24-089329.json
- Plain text: https://secwatch.observer/filing/0000950170-24-089329.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.